Dianthus therapeutics highlights recent business achievements and reports q2 financial results

Phase 2 magic trial of claseprubart (dnth103) in generalized myasthenia gravis (gmg) top-line results anticipated in september 2025; the first of three catalysts for the claseprubart neuromuscular franchise by ye'26
DNTH Ratings Summary
DNTH Quant Ranking